14 completed. 14 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 14 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow immunologic technique: new trials by email Literature Review of immunologic technique trials Research Report on immunologic technique
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer pazopanib hydrochloride, laboratory biomarker analysis, immunologic technique - Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer | Phase 2 | Completed | City of Hope Medical Center | 28 | 2010-12-08 | 2022-06-08 |
| Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma epirubicin hydrochloride, sulindac, immunologic technique - Melanoma (Skin) | Phase 2 | Completed | Cancer Trials Ireland | 32 | 2007-08-01 | 2014-12-31 |
| Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Bevacizumab in Treating Patients With Primary Liver Cancer That Cannot be Removed by Surgery bevacizumab, dexamethasone, floxuridine - Liver Cancer | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 22 | 2007-05-09 | 2024-12-10 |
| Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment erlotinib hydrochloride, gene expression analysis, protein expression analysis - Lung Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 40 | 2006-09-01 | 2010-08-09 |
| Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes alemtuzumab, arsenic trioxide, azacitidine - Leukemia, Myelodysplastic Syndromes | Phase 2 / Phase 3 | Completed | The University of New South Wales | 2000 | 2006-08-01 | 2013-08-26 |
| Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant alemtuzumab, methylprednisolone, prednisone - Breast Cancer, Chronic Myeloproliferative Disorders | Phase 2 | Completed | Fred Hutchinson Cancer Center | 53 | 2006-07-01 | 2010-05-14 |
| Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy sargramostim, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis - Brenner Tumor, Fallopian Tube Cancer | Phase 2 | Completed | University of Washington | 21 | 2006-05-01 | 2017-08-28 |
| Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery celecoxib, recombinant interferon alfa-2b, polymerase chain reaction - Renal Cell Cancer, Stage IV Renal Cell Cancer | Phase 2 | Completed | Case Comprehensive Cancer Center | 17 | 2006-03-01 | 2012-08-07 |
| Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer DNA analysis, immunologic technique, pharmacological study - Brain and Central Nervous System Tumors, Intraocular Melanoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 78 | 2006-01-01 | 2024-04-04 |
| Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma bortezomib, immunologic technique, samarium Sm 153 lexidronam pentasodium - Multiple Myeloma and Plasma Cell Neoplasm | Phase 1 / Phase 2 | Completed | Mayo Clinic | 50 | 2005-09-01 | 2011-05-11 |
| Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma bevacizumab, erlotinib hydrochloride, fluorescence in situ hybridization - Melanoma | Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 34 | 2004-09-01 | 2013-07-22 |
| Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer HER-2/neu intracellular domain protein, leukapheresis, laboratory biomarker analysis - HER2-positive Breast Cancer, Male Breast Cancer | Phase 2 | Completed | University of Washington | 38 | 2004-03-01 | 2020-02-12 |
| Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus fludarabine phosphate, cyclophosphamide, Rituxan (rituximab) - Lupus Erythematosus, Systemic | Phase 2 | Completed | National Cancer Institute (NCI) | 9 | 2004-01-30 | 2021-01-05 |
| Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation therapeutic allogeneic lymphocytes, aldesleukin, peripheral blood stem cell transplantation - Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 37 | 2002-09-01 | 2017-03-29 |
Congenital Abnormalities (3) · Melanoma (3) · Anemia, Refractory, with Excess of Blasts (2) · Breast Neoplasms (2) · Carcinoma, Ovarian Epithelial (2) · Carcinoma, Renal Cell (2) · Leukemia (2) · Leukemia, Myeloid, Acute (2) · Leukemia, Myelomonocytic, Chronic (2) · Lung Neoplasms (2) · Multiple Myeloma (2) · Myelodysplastic Syndromes (2) · Neoplasms, Plasma Cell (2) · Neuroblastoma (2) · Ovarian Neoplasms (2)
Fred Hutchinson Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · University of Washington (2) · Cancer Trials Ireland (1) · Case Comprehensive Cancer Center (1) · City of Hope Medical Center (1) · Mayo Clinic (1) · National Cancer Institute (NCI) (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · The University of New South Wales (1) · Vanderbilt-Ingram Cancer Center (1)
United States (12) · Ireland (1) · United Kingdom (1)
Alan K. Burnett, MD, FRCP (1) · Angela Dispenzieri, MD (1) · Barbara Goff (1) · Brian Rini (1) · Charles M. Rudin, MD, PhD (1) · Jeffrey A. Sosman, MD (1) · John Crown, MD (1) · Kim Kramer, MD (1) · Mary Disis (1) · Merav Bar (1) · Paul Carpenter, MD (1) · Steven Pavletic, M.D. (1) · Sumanta Pal (1) · William R. Jarnagin, MD (1)
PMID 21677464, PMID 21873334, PMID 34875023
P01CA018029 (1), P30CA006973 (1), P30CA015083 (1)